Skip to content
Op2Lysis

Op2Lysis

A new hope for hemorrhagic stroke

  • About Op2Lysis
  • Newsfeed
  • -EN-
  • -FR-

Orphan drug designation for OptPA

Op2Lysis SAS is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to OptPA for treatment of intracerebral hemorrhage.

Orphan Drug Designation – EnglishTélécharger
Author Jérôme PARCQPosted on 9 November 20219 November 2021Categories News

Post navigation

Previous Previous post: Who are we? Meet Kathy Van Butsele – CMC Management and Regulatory
Next Next post: EIC Accelerator – October 2021 (cut-off#6)

Latest News

  • Who are we? Meet Audrey Thiebaut – R&D Project Manager 14 April 2022
  • Retrospective 2021 27 January 2022
  • EIC Accelerator – October 2021 (cut-off#6) 6 January 2022
  • About Op2Lysis
  • Newsfeed
  • -EN-
  • -FR-
Op2Lysis Proudly powered by WordPress